Drug Profile

PP 0121

Alternative Names: PHAGOBURN E coli phage - PHAXIAM Therapeutics; PP0121

Latest Information Update: 28 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pherecydes Pharma
Developer PHAXIAM Therapeutics
Class Coliphages
Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Sep 2023 Phaxiam announces intention to submit Clinical Trial Application to France for Urinary tract infections before the end of 2023
26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
16 Jun 2020 Discontinued - Phase-I/II for Burn infections in France, before June 2020 (Topical) (Pherecydes Pharma pipeline, June 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com